By what way Physician can Enhance Outcomes in Patients with metastatic Malignant Melanoma
Introduction:The incidence of malignant melanoma is increasing at a rate greater than any other human cancer. Although melanoma accounts for only 4 percent of all dermatologic cancers, it is responsible for 80 percent of deaths from skin cancer; only 14 percent of patients with metastatic melanoma s...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2012-03-01
|
| Series: | International Journal of Hematology-Oncology and Stem Cell Research |
| Subjects: | |
| Online Access: | https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/322 |
| _version_ | 1827837927000899584 |
|---|---|
| author | Mehrdad Payandeh Mehrnoush Aeinfar Ali Maleki Mmohammad Erfan Zare |
| author_facet | Mehrdad Payandeh Mehrnoush Aeinfar Ali Maleki Mmohammad Erfan Zare |
| author_sort | Mehrdad Payandeh |
| collection | DOAJ |
| description | Introduction:The incidence of malignant melanoma is increasing at a rate greater than any other human cancer. Although melanoma accounts for only 4 percent of all dermatologic cancers, it is responsible for 80 percent of deaths from skin cancer; only 14 percent of patients with metastatic melanoma survive for five years. The optimal therapy varies with the stage of the disease. Surgical excision is the treatment of choice for early disease, while some patients who are at high risk for developing metastatic disease (particularly those with stage II and III cancers may benefit from adjuvant therapy with interferon alfa (IFNa).(1) The management of patients with disseminated disease is a difficult problem. In carefully selected patients, excision of limited distant metastases can occasionally produce durable benefit. However, most patients with stage IV disease require systemic treatment. Traditional systemic treatment approaches include cytotoxic chemotherapy and immunotherapy. Several novel therapeutic approaches are under study, the most promising of which target specific molecular abnormalities that have been identified in melanomas. Molecularly targeted therapy for advanced melanoma will be reviewed here.(2) |
| first_indexed | 2024-03-12T06:56:21Z |
| format | Article |
| id | doaj.art-ab7f2e0d2f184721a1cd573bf8648c41 |
| institution | Directory Open Access Journal |
| issn | 2008-2207 |
| language | English |
| last_indexed | 2024-03-12T06:56:21Z |
| publishDate | 2012-03-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | International Journal of Hematology-Oncology and Stem Cell Research |
| spelling | doaj.art-ab7f2e0d2f184721a1cd573bf8648c412023-09-03T00:03:06ZengTehran University of Medical SciencesInternational Journal of Hematology-Oncology and Stem Cell Research2008-22072012-03-0161By what way Physician can Enhance Outcomes in Patients with metastatic Malignant MelanomaMehrdad Payandeh0Mehrnoush Aeinfar1Ali Maleki2Mmohammad Erfan Zare3Department of hematology, Kermanshah University of Medical Sciences, Kermanshah, IranDepartment of Hematology, Kermanshah University of Medical Sciences, Kermanshah, IranHematology Center , Kermanshah University of Medical Sciences, IranStudent of Research Center , Kermanshah University of Medical Sciences, IranIntroduction:The incidence of malignant melanoma is increasing at a rate greater than any other human cancer. Although melanoma accounts for only 4 percent of all dermatologic cancers, it is responsible for 80 percent of deaths from skin cancer; only 14 percent of patients with metastatic melanoma survive for five years. The optimal therapy varies with the stage of the disease. Surgical excision is the treatment of choice for early disease, while some patients who are at high risk for developing metastatic disease (particularly those with stage II and III cancers may benefit from adjuvant therapy with interferon alfa (IFNa).(1) The management of patients with disseminated disease is a difficult problem. In carefully selected patients, excision of limited distant metastases can occasionally produce durable benefit. However, most patients with stage IV disease require systemic treatment. Traditional systemic treatment approaches include cytotoxic chemotherapy and immunotherapy. Several novel therapeutic approaches are under study, the most promising of which target specific molecular abnormalities that have been identified in melanomas. Molecularly targeted therapy for advanced melanoma will be reviewed here.(2)https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/322Malignant MelanomaBRAF MutationVemurafenibIpilimumab |
| spellingShingle | Mehrdad Payandeh Mehrnoush Aeinfar Ali Maleki Mmohammad Erfan Zare By what way Physician can Enhance Outcomes in Patients with metastatic Malignant Melanoma International Journal of Hematology-Oncology and Stem Cell Research Malignant Melanoma BRAF Mutation Vemurafenib Ipilimumab |
| title | By what way Physician can Enhance Outcomes in Patients with metastatic Malignant Melanoma |
| title_full | By what way Physician can Enhance Outcomes in Patients with metastatic Malignant Melanoma |
| title_fullStr | By what way Physician can Enhance Outcomes in Patients with metastatic Malignant Melanoma |
| title_full_unstemmed | By what way Physician can Enhance Outcomes in Patients with metastatic Malignant Melanoma |
| title_short | By what way Physician can Enhance Outcomes in Patients with metastatic Malignant Melanoma |
| title_sort | by what way physician can enhance outcomes in patients with metastatic malignant melanoma |
| topic | Malignant Melanoma BRAF Mutation Vemurafenib Ipilimumab |
| url | https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/322 |
| work_keys_str_mv | AT mehrdadpayandeh bywhatwayphysiciancanenhanceoutcomesinpatientswithmetastaticmalignantmelanoma AT mehrnoushaeinfar bywhatwayphysiciancanenhanceoutcomesinpatientswithmetastaticmalignantmelanoma AT alimaleki bywhatwayphysiciancanenhanceoutcomesinpatientswithmetastaticmalignantmelanoma AT mmohammaderfanzare bywhatwayphysiciancanenhanceoutcomesinpatientswithmetastaticmalignantmelanoma |